Pharmaceutical

Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

Using their SPID®-Technology, Laxxon Medical has manufactured a 3D printed oral tablet combining a GLP-1 receptor agonist and a permeation…

5 months ago

GE HealthCare Tops List for Third Year in a Row with Highest Number of AI-Enabled Medical Device Authorizations

FDA’s list of AI-enabled device authorizations includes more than 850 devices; 72 are from GE HealthCare – more than any…

5 months ago

Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

- Serena Hung, M.D., and Jeffrey Young will support company’s continued progress, including two planned IND submissions in 2025 -BOSTON--(BUSINESS…

5 months ago

Rapid Dose Therapeutics and McMaster University’s Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery

Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on…

5 months ago

Halberd/Athena GTX Research Promises a Much Brighter Future

Walt Disney once said, "All our dreams can come true if we have the courage to pursue them".JACKSON CENTER, PA…

5 months ago

IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics…

5 months ago

Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food…

5 months ago

Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

5 months ago

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading…

5 months ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds…

5 months ago